FDAnews Drug Daily Bulletin

OCERA THERAPEUTICS, INC. RAISES $12 MILLION SERIES B FINANCING

July 11, 2006
A A

Ocera Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of clinical candidates for the treatment of gastrointestinal and liver diseases announced today that it has raised a $12 million Series B financing. The financing will be used to continue clinical development of the company's first product, AST-120. A pivotal Phase III clinical trial for AST-120 was initiated in the first quarter of 2006 for the treatment of fistulizing Crohn's disease. The Series B round was led by new investor, Sofinnova Ventures. Previous investors, Domain Associates, LLC and Thomas, McNerney & Partners, LLC also participated in this financing.
BioSpace